Literature DB >> 11722712

Oral administration of milk from cows immunized with human intestinal bacteria leads to significant improvements of symptoms and signs in patients with oral submucous fibrosis.

Y S Tai1, B Y Liu, J T Wang, A Sun, H W Kwan, C P Chiang.   

Abstract

BACKGROUND: Previous studies have shown that the local and systemic upregulation of fibrogenic cytokines and downregulation of antifibrotic cytokine are central to the pathogenesis of oral submucous fibrosis (OSF). The milk from cows immunized with human intestinal bacteria (immune milk) contains an anti-inflammatory component that may suppress the inflammatory reaction and modulate cytokine production. Therefore, it was decided to test whether immune milk may have some beneficial effects on controlling the symptoms and signs in OSF patients.
METHODS: In this preliminary study, 26 OSF patients who received immune milk treatment (45 g of immune milk powder twice a day) for 3 months and oral habit intervention were included in the experimental group. Another 20 OSF patients who received only oral habit intervention served as the control group.
RESULTS: We found that the interincisor distance was significantly improved (> or =3 mm of the baseline measurement) in 18 of the 26 (69.2%) OSF patients in the experimental group at exit. However, in the control group none of the OSF patients had an increase in interincisor distance greater than 2 mm. In addition, disappearance or significant improvement of symptoms at exit was observed in 80% (16/20) of the patients with intolerance to spicy foods (P < 0.001) and 72.2% (13/18) of the patients with xerostomia (P < 0.005) in the experimental group, compared with 17.6% (3/17) of the patients with improvement of intolerance to spicy foods and 15.4% (2/13) of the patients with improvement of xerostomia in the control group. Partial regression of concomitant oral leukoplakia or erythroplakia (judged from the size reduction of the lesions) at exit was noted in 71.4% (5/7) of the patients in the experimental group (P < 0.05), compared with none (0/5) of the patients with improvement in the control group.
CONCLUSION: We conclude that oral administration of immune milk leads to significant improvements of symptoms and signs in OSF patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11722712     DOI: 10.1034/j.1600-0714.2001.301007.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  7 in total

Review 1.  Management of oral submucous fibrosis: an overview.

Authors:  Punnya V Angadi; Sanjay Rao
Journal:  Oral Maxillofac Surg       Date:  2010-09

2.  Spirulina and pentoxyfilline - a novel approach for treatment of oral submucous fibrosis.

Authors:  Bhavana Sujana Mulk; Prasannasrinivas Deshpande; Nagalakshmi Velpula; Vani Chappidi; Raja Lakshmi Chintamaneni; Stuti Goyal
Journal:  J Clin Diagn Res       Date:  2013-12-15

Review 3.  Perspectives on immunoglobulins in colostrum and milk.

Authors:  Walter L Hurley; Peter K Theil
Journal:  Nutrients       Date:  2011-04-14       Impact factor: 5.717

Review 4.  Comparative Efficacy of Interventions for the Management of Oral Submucous Fibrosis: A Systematic Review and Network Meta-Analysis.

Authors:  Divya Gopinath; Lai Mong Hui; Sajesh K Veettil; Athira Balakrishnan Nair; Mari Kannan Maharajan
Journal:  J Pers Med       Date:  2022-08-01

Review 5.  Oral submucous fibrosis: an update.

Authors:  Uwe Wollina; Shyam B Verma; Fareedi Mukram Ali; Kishor Patil
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-04-13

6.  Pathogenesis and therapeutic intervention of oral submucous fibrosis.

Authors:  Thukanaykanpalayam Ragunathan Yoithapprabhunath; Thangadurai Maheswaran; Janardhanam Dineshshankar; Abraham Anusushanth; Pandian Sindhuja; Govindasamy Sitra
Journal:  J Pharm Bioallied Sci       Date:  2013-06

Review 7.  Oral submucous fibrosis: Newer proposed classification with critical updates in pathogenesis and management strategies.

Authors:  Deepak Passi; Prateek Bhanot; Dhruv Kacker; Deepak Chahal; Mansi Atri; Yoshi Panwar
Journal:  Natl J Maxillofac Surg       Date:  2017 Jul-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.